Trials / Unknown
UnknownNCT02452606
Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the genetic variants of clock and narcolepsy genes that determine the therapeutic effects of Stalevo® on the quality of sleep in patients with Parkinson's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Stalevo® | * Sleep disorders in Parkinson's disease * Analysis by Parkinson's Disease Sleep Scale(PDSS) scores. * If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective. |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
- First posted
- 2015-05-22
- Last updated
- 2016-07-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02452606. Inclusion in this directory is not an endorsement.